Brief: AcelRx Pharmaceuticals Says On April 26, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
28/04/2023 21:39
April 28 (Reuters) - AcelRx Pharmaceuticals Inc
ACRX.O :
* ACELRX PHARMACEUTICALS - ON APRIL 26, RECEIVED NOTICE OF
DELISTING/FAILURE TO SATISFY CONTINUED LISTING RULE/STANDARD;
TRANSFER OF LISTING FROM NASDAQ
Further company coverage: ACRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial